The company ‘Merck’, which is also known as MSD outside of the USA and Canada, have recently announced, the presentation of the data, collected from the HIC clinical development program of the company at the 11th International AIDS Society Conference on HIV Science starting from 18th July 2021 to 21st July 2021.
The presentations are going to feature the data for ‘islatravir’, which has been an investigational nucleoside reverse transcriptase translocation inhibitor, that is currently being used for the purpose of evaluation across the variety of vaccine doses, along with the frequencies and formulations for the treatment of the infection ‘HIV-1’ in the combination with the other antiretroviral agents and for the treatment of the HIV-1 as a monotherapy.
The data has also been including the results collected from a Phase 2a study, which was conducted for the evaluation of the safety and pharmacokinetics (PK) of the oral islatravir for the pre-exposure prophylaxis (PrEP) through the process of 24 weeks.
The company Merck is also going to share a safety data of 96-weeks for once in a daily islatravir in the combination with doravirine, which was used in the previously untreated people suffering with the HIV-1 Infection, and the company is also going to be providing the updates from the Phase-3 trial evaluation in the previously untreated participants with the disease HIV-1.
Dr. Joan Butterton, vice president at Merck Research Laboratories said, their years-long commitment for fighting against the epidemic has now been stronger than ever as they are going to continue building on their legacy of their innovation and research.
Writing is a medium to express feelings and convey facts. A creative mind never rests in peace and this amazing platform gives me the freedom to write about what I like most.
I’ve been a writer/blogger for the last twelve years and have covered technology-related topics. However, I also have considerable years of experience in writing for various domains – Technology, Beauty, Fashion, Pharmaceutical, human psychology etc. Technology is my forte.
I’ve handled many interesting projects. Writing is my passion. As an author, I’ve learned a lot in my long journey of penning down my thoughts!
